RxDoctor Payments Data

Eric Larson, MD

Ophthalmology · Oshkosh, WINPI 1275513467

Payments from drug & device makers

$2,004in general payments, 2019–2025

Across 53 payments — averaging $37.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eyepoint US, Inc.$750
  • Alcon$708
  • AbbVie$215
  • Kala Pharmaceuticals, Inc.$107
  • Rayner Intraocular Lenses Limited$96
  • GSK$34
  • plus $94 from 5 others

What the payments were for

  • Consulting fees$75037%
  • Food & beverage$1,25463%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,004 in reported general payments places this provider in the 75th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$429,001
Medicare patients
647
Services billed
1,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate33$20,614
RestasisCyclosporine13$13,246
Latanoprost908$12,309
Prednisolone Acetate296$11,477
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat480$10,659
Cyclosporine16$10,585
LumiganBimatoprost24$9,645
Loteprednol Etabonate39$8,561
Timolol Maleate161$5,064
Travoprost27$3,451
MoxifloxacinMoxifloxacin Hcl91$3,220
Fluorometholone34$2,881
TafluprostTafluprost/Pf15$2,754
ValacyclovirValacyclovir Hcl39$1,480
Brimonidine Tartrate101$1,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$215$22,89137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Oshkosh

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →